



HAL
open science

Identification of inhibitors of the immunosuppressive enzyme IL4I1

Marc Presset, Diana Djordjevic, Aurélie Dupont, Erwan Le Gall, Valérie Molinier-Frenkel, Flavia Castellano

► **To cite this version:**

Marc Presset, Diana Djordjevic, Aurélie Dupont, Erwan Le Gall, Valérie Molinier-Frenkel, et al.. Identification of inhibitors of the immunosuppressive enzyme IL4I1. *Bioorganic Chemistry*, 2020, 94, pp.103463 -. 10.1016/j.bioorg.2019.103463 . hal-03489604

HAL Id: hal-03489604

<https://hal.science/hal-03489604>

Submitted on 7 Mar 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

1 **Identification of inhibitors of the immunosuppressive enzyme IL4I1**

2

3

4 Marc Passet¹, Diana Djordjevic^{2,3}, Aurélie Dupont^{2,3}, Erwan Le Gall¹, Valérie Molinier-Frenkel^{2,3,4*},
5 and Flavia Castellano^{2,3*}

6

7 ¹ Electrochimie et Synthèse Organique, Université Paris Est, ICMPE (UMR 7182), CNRS, UPEC, 2 rue

8 Henri Dunant, F-94320 Thiais, France ;

9 ² INSERM, U955, Equipe 09, Créteil, France;

10 ³ Université Paris Est, Faculté de Médecine, Créteil, France;

11 ⁴ AP-HP, Hôpital H. Mondor - A. Chenevier, Laboratoire d'Immunologie, Créteil, France.

12

13 * Equal participation

14

15

16 Corresponding authors: Flavia Castellano and Valérie Molinier-Frenkel, INSERM U955, IMRB eq 09,
17 Hôpital Henri Mondor, 51 av du Maréchal de Lattre de Tassigny, F-94010 Créteil cedex, France;
18 flavia.castellano@inserm.fr, valerie.frenkel@inserm.fr, Tel: +33 1 49 813765, Fax: +33 1 49813566.

19

20 **Running title: identification of IL4I1 inhibitors**

21

22 **Key words:** immunosuppressive enzymes, cancer therapy, inhibitors, phenylalanine derivatives

23

24

25

1 INTRODUCTION

2 Recent advances in cancer immunotherapy have shown that limiting local or systemic
3 cancer-related immunosuppression can result in long-lasting clinical responses. Amino-acid
4 catabolizing enzymes reduce the availability of essential or semi-essential amino acids, while
5 producing toxic products. Both effects result in impaired anti-tumor T-cell responses and the
6 promotion of tumor growth [1]. Interleukin-4 Induced gene 1 (IL4I1) is a secreted L-phenylalanine
7 oxidase expressed by antigen-presenting cells. *In vitro*, IL4I1 inhibits T-cell proliferation and cytokine
8 production and facilitates the differentiation of naïve CD4⁺ T cells into regulatory T cells, in part *via*
9 its capacity to produce H₂O₂ and deplete phenylalanine from the T-cell microenvironment. IL4I1 is
10 strongly detected in the tumor bed of most human tumor types and, in some cases, such as certain
11 B cell lymphomas, it is expressed by the tumor cells themselves [2]. Local production of IL4I1
12 facilitates tumor growth in mouse models by inhibiting the proliferation and function of anti-tumor
13 CD8⁺ T cells and altering the balance of immune cells in the tumor microenvironment towards
14 immunosuppressive populations [3, 4]. Moreover, the localization and density of IL4I1-expressing
15 cells correlates with pejorative clinical parameters and tend to predict shorter survival in patients
16 suffering from melanoma [5]. A correlation between the presence of the IL4I1 protein or mRNA in
17 the tumor and prognosis has also been observed in renal carcinoma, glioma (The Human Protein
18 Atlas) [6], colon cancer [7] and breast cancer [8]. These data all suggest that therapeutic strategies
19 aimed at inhibiting IL4I1 expression or activity in cancer patients may improve immune control of
20 the tumor, without harming the host, as the absence of IL4I1 in KO mice does not appear to result in
21 specific pathologies or premature death [9]. Targeting IL4I1 activity in the context of cancer
22 treatment could thus become a new immunotherapy approach [10].

23 Phenylalanine (Phe) is the preferred substrate of IL4I1 catalytic activity. Our group has
24 developed an approach for straightforward three-component reductive coupling between organic
25 halides, amines, and aldehyde derivatives to produce α -branched amines [11],[12]. Here, we
26 applied this method to synthesize 21 distinct phenylalanine derivatives and tested them, together
27 **with** other 7 commercially available phenylalanine derivatives, as potential inhibitors of IL4I1
28 activity. Seven molecules inhibited IL4I1 enzymatic activity in the micromolar range and three of
29 them were not toxic *in vitro*. One could reverse the negative effect of IL4I1 on T-cell proliferation in
30 cell cultures. This work paves the way for the future development of clinically effective IL4I1
31 inhibitors.

2 METHODS

2.1 Chemical compounds (Cps)

Cp1 (ethyl 2-(4-methylpiperazin-1-yl)-3-phenylpropanoate), **Cp2** (ethyl propylphenylalaninate), **Cp3** (ethyl 3-(2,6-dichlorophenyl)-2-(piperidin-1-yl)propanoate), **Cp4** (ethyl 2-morpholino-3-phenylpropanoate), **Cp5** (ethyl 3-phenyl-2-(piperidin-1-yl)propanoate), **Cp6** (ethyl diethylphenylalaninate), **Cp7** (ethyl phenylphenylalaninate), **Cp8** (ethyl 2-(allylamino)-3-(3-(trifluoromethyl)phenyl)propanoate), and **Cp9** (ethyl 3-(4-cyanophenyl)-2-(phenylamino)propanoate) were prepared as described in [C. Haurena, E. Le Gall, S. Sengmany, T. Martens, M. Troupel, *J. Org. Chem.* **2010**, 75, 2645-2650]. **Commercial phenylalanine derivatives : 3-(4-pyridyl)-L-alanine (Cp10)**, 1-methyl tryptophane (**Cp11**), benzoic acid, 3,4-dihydroxy-L-phenylalanine (**Cp12**), L-phenylalanine ethyl ester (**Cp13**), *N*-acetyl-phenylalanine (**Cp14**), 2-fluoro-phenylalanine (**Cp15**) were purchased from Sigma-Aldrich and used as received.

General procedure: In air, Zn (3.3 equiv) was placed in a round-bottom flask equipped with a stir bar and the flask closed with a septum and purged with Ar. CH₃CN (C = 0.25 M) and TFA (0.1 equiv) were added and the flask heated to reflux and then cooled to room temperature (RT). Benzyl halide (3.0 equiv) was added and the mixture was stirred at rt (for bromides) or at 60 °C (for chlorides) for 1 h. In air, a 2-necked round-bottom flask equipped with a stir bar, a condenser and an addition funnel was charged with ethyl glyoxylate (1.1 equiv) and the amine (1.0 equiv). The solution of organozinc halide in CH₃CN was then added dropwise and the reaction was stirred at rt for 14 h. Then, the reaction mixture was poured into saturated aqueous NH₄Cl and the solution extracted twice with AcOEt. The combined organic layers were washed with brine, dried (Na₂SO₄) and evaporated to give the crude product, which was purified by an acid/base work-up, as described in the above-mentioned reference.

Cp2-SO4 was prepared as follows. H₂SO₄ (53 μL, 1.0 mmol, 0.5 equiv) was added to a solution of **Cp2** (0.49 g, 2.0 mmol) in anhydrous Et₂O (8 mL, C = 0.25 M) and the solution stirred at RT for 1 h. Then, the supernatant was removed and the paste dried to give the title compound as a sticky paste (333 mg, 50%). ¹H NMR (400 MHz, CDCl₃): δ 7.21 (s, 5H), 4.12 (dd, *J* = 10.1, 4.8 Hz, 1H), 4.04 (q, *J* = 7.1 Hz, 2H), 3.64 (dd, *J* = 13.4, 6.6 Hz, 1H), 3.26 (dd, *J* = 13.5, 10.5 Hz, 1H), 3.04-2.93 (m, 2H), 1.87-1.85 (m, 2H), 1.01 (t, *J* = 7.1 Hz, 3H), 0.87 (t, *J* = 7.4 Hz, 3H) [2 NH not detected]. HRMS (ESI/Q-TOF) *m/z*: [M+H]⁺ Calcd for C₁₄H₂₅NO₂S 236.1645; Found 236.1645.

1
2 **Cp2-HCl** was prepared as follows. A solution of **Cp2** (0.5 g, 2.1 mmol) in anhydrous Et₂O (20 mL, C =
3 0.1 M) was saturated with gaseous HCl (prepared by the addition of concentrated H₂SO₄ to NaCl)
4 and the solution stirred at RT for 1 h. Then, the suspension was filtered on a fritted funnel and the
5 solid dried to give the title compound as a white solid (0.57 g, 99%). ¹H NMR (400 MHz, MeOD): δ
6 7.37-7.31 (m, 5H), 4.33 (dd, *J* = 8.5, 5.4 Hz, 1H), 4.15 (q, *J* = 7.1 Hz, 2H), 3.49 (dd, *J* = 13.6, 5.1 Hz, 1H),
7 3.18 (dd, *J* = 13.6, 9.3 Hz, 1H), 3.10-3.00 (m, 2H), 1.84-1.78 (m, 2H), 1.10 (t, *J* = 7.1 Hz, 3H), 1.03 (t, *J* =
8 7.4 Hz, 3H) [2 NH not detected].

9
10 **Cp2-TFA** was prepared as follows. TFA (0.16 mL, 2.0 mmol, 1.0 equiv) was added to a solution of Cp2
11 (0.49 g, 2.0 mmol) in anhydrous Et₂O (8 mL, C = 0.25 M) and the solution stirred at RT for 1 h. Then,
12 the suspension was filtered on a fritted funnel and the solid dried to give the title compound as a
13 white solid (154 mg, 20%). ¹H NMR (400 MHz, CDCl₃): δ 7.31-7.28 (m, 3H), 7.21-7.19 (m, 2H), 4.13-
14 4.07 (m, 3H), 3.44 (dd, *J* = 13.5, 4.8 Hz, 1H), 3.19 (dd, *J* = 13.4, 10.0 Hz, 1H), 3.08-3.01 (m, 1H), 2.98-
15 2.91 (m, 1H), 1.83-1.78 (m, 2H), 1.08 (t, *J* = 7.1 Hz, 3H), 0.97 (t, *J* = 7.4 Hz, 3H) [2 NH not detected].
16 ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 168.1 (C), 162.3 (q, *J* = 35.8 Hz, C), 134.0 (C), 129.1 (2 CH), 128.8 (2
17 CH), 127.6 (CH), 62.3 (CH₂), 61.3 (CH), 48.4 (CH₂), 36.0 (CH₂), 19.6 (CH₂), 13.6 (CH₃), 11.0 (CH₃) [CF₃
18 not detected]. ¹⁹F NMR (376 MHz, CDCl₃): δ -75.7 (s, 3F).

19
20 **Cp7Bis** (ethyl (2-(2-ethoxy-1-hydroxy-2-oxoethyl)phenyl)phenylalaninate) was isolated as a side-
21 product of the preparation of **Cp7** during flash chromatography on a silica gel. ¹H NMR (400 MHz,
22 CDCl₃): (2 diastereomers) δ 7.29 (s, 8H), 7.18-7.13 (m, 4H), 6.74 (dd, *J* = 7.3, 7.3 Hz, 2H), 6.60 (dd, *J* =
23 8.7, 8.7 Hz, 4H), 5.51 (s, 1H), 5.45 (s, 1H), 4.57 (br s, 2H), 4.42 (br s, 2H), 4.32-4.11 (m, 8H), 3.80 (br s,
24 1H), 3.73 (br s, 1H), 3.33-3.26 (m, 4H), 1.25-1.15 (m, 12H). ¹³C{¹H} NMR (100 MHz, CDCl₃): (2
25 diastereomers) δ 173.8 (C), 173.8 (C), 173.5 (2 C), 146.6 (C), 146.6 (C), 137.3 (C), 137.2 (C), 135.5 (C),
26 135.2 (C), 130.8 (CH), 130.6 (CH), 129.2 (2 CH), 129.2 (2 CH), 128.7 (CH), 128.7 (CH), 127.8 (CH),
27 127.6 (CH), 127.5 (CH), 127.3 (CH), 118.5 (CH), 118.4 (CH), 113.7 (2 CH), 113.6 (2 CH), 70.4 (CH), 70.0
28 (CH), 62.2 (CH₂), 62.2 (CH₂), 61.3 (CH₂), 61.1 (CH₂), 58.4 (CH), 58.3 (CH), 35.7 (CH₂), 35.6 (CH₂), 14.0
29 (4 CH₃). HRMS (ESI/Q-TOF) *m/z*: [M+H]⁺ Calcd for C₂₁H₂₆NO₅ 372.1805; Found 372.1811.

30
31 **Cp2-pMe** (ethyl 2-(propylamino)-3-(*p*-tolyl)propanoate): The general procedure performed with 4-
32 methylbenzyl bromide (1.39 g, 7.5 mmol, 3.0 equiv), ethyl glyoxylate (0.64 mL, 50% in toluene,
33 2.75 mmol, 1.1 equiv) and *n*-propylamine (0.20 mL, 2.5 mmol, 1.0 equiv) afforded the title

1 compound (426 mg, 68%) as a yellow oil. ¹H NMR (400 MHz, CDCl₃): δ 7.05 (s, 4H), 4.07 (q, *J* = 7.1
2 Hz, 2H), 3.45 (t, *J* = 7.0 Hz, 1H), 2.89 (dd, *J* = 8.8, 7.1 Hz, 2H), 2.53 (ddd, *J* = 11.1, 8.1, 6.7 Hz, 1H), 2.42
3 (ddd, *J* = 11.1, 8.1, 6.2 Hz, 1H), 2.28 (s, 3H), 1.62 (br s, 1H), 1.47-1.40 (m, 2H), 1.13 (t, *J* = 7.0 Hz, 3H),
4 0.85 (t, *J* = 7.4 Hz, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 174.5 (C), 135.8 (C), 134.0 (C), 128.8 (2 CH),
5 128.8 (2 CH), 62.9 (CH), 60.2 (CH₂), 49.8 (CH₂), 39.1 (CH₂), 23.0 (CH₂), 20.8 (CH₃), 13.9 (CH₃), 11.4
6 (CH₃). HRMS (ESI/Q-TOF) *m/z*: [M+H]⁺ Calcd for C₁₅H₂₄NO₂ 250.1801; Found 250.1801.

7
8 **Cp2-mMe** (ethyl 2-(propylamino)-3-(*m*-tolyl)propanoate): The general procedure performed with 3-
9 methylbenzyl bromide (1.0 mL, 7.5 mmol, 3.0 equiv), ethyl glyoxylate (0.64 mL, 50% in toluene,
10 2.75 mmol, 1.1 equiv) and *n*-propylamine (0.20 mL, 2.5 mmol, 1.0 equiv) afforded the title
11 compound (432 mg, 69%) as a yellow oil. ¹H NMR (400 MHz, CDCl₃): δ 7.15 (dd, *J* = 7.4, 7.4 Hz, 1H),
12 7.02-6.97 (m, 3H), 4.09 (q, *J* = 7.0 Hz, 2H), 3.48 (t, *J* = 7.0 Hz, 1H), 2.96-2.84 (m, 2H), 2.57-2.51 (m,
13 1H), 2.43 (ddd, *J* = 11.1, 8.1, 6.3 Hz, 1H), 2.31 (s, 3H), 1.64 (br s, 1H), 1.49-1.42 (m, 2H), 1.14 (t, *J* =
14 7.0 Hz, 3H), 0.86 (t, *J* = 7.4 Hz, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 174.7 (C), 137.7 (C), 137.2 (C),
15 129.9 (CH), 128.1 (CH), 127.2 (CH), 126.1 (CH), 63.0 (CH), 60.3 (CH₂), 49.9 (CH₂), 39.6 (CH₂), 23.1
16 (CH₂), 21.2 (CH₃), 14.1 (CH₃), 11.5 (CH₃). HRMS (ESI/Q-TOF) *m/z*: [M+H]⁺ Calcd for C₁₅H₂₄NO₂
17 250.1801; Found 250.1802.

18
19 **Cp2-sulfamide** (ethyl *N*-(methylsulfonyl)-*N*-propylphenylalaninate) was prepared as follows.
20 Triethylamine (0.3 mL, 2.0 mmol, 2.0 equiv) and mesyl chloride (0.1 mL, 1.1 mmol, 1.1 equiv) was
21 added to a solution of **Cp2** (235 mg, 1.0 mmol) in CH₂Cl₂ (2 mL) at 0 °C under Ar and the reaction
22 stirred at 0 °C for 2 h. Then, the reaction mixture was poured into saturated aqueous NH₄Cl (10 mL)
23 and extracted twice with CH₂Cl₂ (2x10 mL). The combined organic layers were dried (Na₂SO₄) and
24 evaporated. Purification of the residue by flash chromatography gave the title compound as a
25 colorless oil (176 mg, 56%). ¹H NMR (400 MHz, CDCl₃): δ 7.32-7.25 (m, 5H), 4.74 (t, *J* = 7.4 Hz, 1H),
26 4.19 (q, *J* = 7.0 Hz, 2H), 3.38 (dd, *J* = 14.1, 7.4 Hz, 1H), 3.28-3.20 (m, 1H), 3.13 – 3.03 (m, 2H), 2.73 (s,
27 3H), 1.69-1.58 (m, 2H), 1.26 (t, *J* = 7.0 Hz, 3H), 0.89 (t, *J* = 7.4 Hz, 3H). ¹³C{¹H} NMR (100 MHz, CDCl₃):
28 δ 170.8 (C), 137.1 (C), 129.3 (2 CH), 128.6 (2 CH), 127.0 (CH), 61.8 (CH), 61.7 (CH₂), 48.0 (CH₂), 39.9
29 (CH₃), 37.0 (CH₂), 23.4 (CH₂), 14.1 (CH₃), 11.4 (CH₃). HRMS (ESI/Q-TOF) *m/z*: [M+H]⁺ Calcd for
30 C₁₅H₂₄NO₄S 314.1420; Found 314.1417.

31
32 **Cp2-sulfamic acid** (1-ethoxy-1-oxo-3-phenylpropan-2-yl)(propyl)sulfamic acid) was prepared as
33 follows. Chlorosulfonic acid (25 μL, 0.38 mmol, 1.1 equiv) was added to a solution of **Cp2** (82 mg,

1 0.35 mmol) in CH₂Cl₂ (2 mL) at 0°C under Ar and the reaction stirred at 0°C for 2 h. Then, the
2 reaction mixture was evaporated and Et₂O (10 mL) added. The resulting mixture was stirred
3 overnight at RT and the suspension filtered on a fritted funnel and the solid dried to give the title
4 compound (89 mg, 80%) as a white solid. ¹H NMR (400 MHz, CDCl₃): δ 8.96 (s, 1H), 7.29-7.24 (m,
5 5H), 4.19 (br s, 1H), 4.07 (q, *J* = 7.1 Hz, 2H), 3.63 (dd, *J* = 13.1, 4.6 Hz, 1H), 3.29 – 3.23 (m, 1H), 3.11
6 (br s, 1H), 2.98 (br s, 1H), 1.93-1.86 (m, 2H), 1.03 (t, *J* = 7.1 Hz, 3H), 0.93 (t, *J* = 7.3 Hz, 3H). ¹³C{¹H}
7 NMR (100 MHz, CDCl₃): δ 168.2 (C), 134.2 (C), 129.5 (2 CH), 128.8 (2 CH), 127.6 (CH), 62.6 (CH), 61.9
8 (CH₂), 49.4 (CH₂), 36.4 (CH₂), 19.6 (CH₂), 13.8 (CH₃), 11.0 (CH₃). HRMS (ESI/Q-TOF) *m/z*: [M–H][–] Calcd
9 for C₁₄H₂₀NO₅S 314.1067; Found 314.1066.

10 **Cp16** (ethyl 3-(2,6-dichlorophenyl)-2-(diethylamino)propanoate): The general procedure performed
11 with 2,6-dichlorobenzyl bromide (3.6 g, 15 mmol, 3.0 equiv), ethyl glyoxylate (1.3 mL, 50% in
12 toluene, 5.5 mmol, 1.1 equiv) and diethylamine (0.52 mL, 5 mmol, 1.0 equiv) afforded the title
13 compound (1.064 g, 67%) as a yellow oil. ¹H NMR (400 MHz, CDCl₃): δ 7.25 d, *J* = 7.9 Hz, 2H), 7.06 (t,
14 *J* = 7.9 Hz, 1H), 4.11 (q, *J* = 7.0, 2H), 3.92 (t, *J* = 7.6 Hz, 1H), 3.39–3.23 (m, 2H), 2.79–2.74 (m, 2H),
15 2.58–2.53 (m, 2H), 1.18 (t, *J* = 7.0 Hz, 3H), 0.93 (t, *J* = 6.9 Hz, 6H). ¹³C{¹H} NMR (100 MHz, CDCl₃): δ
16 172.6 (C), 136.0 (2 C), 135.2 (C), 128.0 (2 CH), 127.8 (CH), 60.7 (CH₂), 60.2 (CH), 44.3 (2 CH₂), 31.5
17 (CH₂) 14.3 (CH₃), 13.8 (2 CH₃). HRMS (ESI/Q-TOF) *m/z*: [M+H]⁺ Calcd for C₁₅H₂₂Cl₂NO₂ 318.1022;
18 Found 318.1020.

19 **Cp17** (ethyl diethylphenylalaninate): The general procedure performed with benzyl chloride (1.9 mL,
20 15 mmol, 3.0 equiv), ethyl glyoxylate (1.3 mL, 50% in toluene, 5.5 mmol, 1.1 equiv) and
21 diethylamine (0.52 mL, 5 mmol, 1.0 equiv) afforded the title compound (0.82 g, 65%) as a yellow oil.
22 ¹H NMR (400 MHz, CDCl₃): δ 7.36–7.11 (m, 5H), 4.10 (ddd, *J* = 6.8, 4.5, 2.1 Hz, 2H), 3.68–3.59 (m,
23 1H), 3.15–3.04 (m, 1H), 2.91 (dd, *J* = 13.4, 6.2 Hz, 1H), 2.81 (ddd, *J* = 14.5, 8.2, 6.4 Hz, 2H), 2.57 (ddd,
24 *J* = 13.3, 6.9, 1.9 Hz, 2H), 1.18 (t, *J* = 7.2 Hz, 3H), 1.05 (t, *J* = 7.1 Hz, 5H). ¹³C{¹H} NMR (100 MHz,
25 CDCl₃): δ 172.6 (C), 138.8 (C), 129.3 (2 CH), 128.2 (2 CH), 126.2 (CH), 65.0(CH), 60.0 (CH₂), 44.5 (2
26 CH₂), 36.4 (CH₂), 14.3 (CH₃), 13.8(2 CH₃). HRMS (ESI/Q-TOF) *m/z*: [M+H]⁺ Calcd for C₁₅H₂₄NO₂
27 250.1801; Found 250.1800.

28 **Cp18** (ethyl 3-(2,6-dichlorophenyl)-2-(propylamino)propanoate): The general procedure performed
29 with 2,6-dichlorobenzyl bromide (3.6 g, 15 mmol, 3.0 equiv), ethyl glyoxylate (1.3 mL, 50% in
30 toluene, 5.5 mmol, 1.1 equiv) and *n*-propylamine (0.4 mL, 5 mmol, 1.0 equiv) afforded the title
31 compound (0.58 g, 38%) as a yellow oil. ¹H NMR (400 MHz, CDCl₃): δ 7.25 (d, *J* = 7.8 Hz, 2H), 7.07 (t, *J*

1 = 7.8 Hz, 1H), 4.08 (q, J = 7.4 Hz, 2H), 3.64–3.61 (m, 1H), 3.26–3.22 (m, 2H), 2.60–2.35 (m, 2H), 1.71
2 (br s, 1H), 1.50–1.35 (m, 2H), 1.11–1.08 (m, 3H), 0.84 (t, J = 9.4 Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz,
3 CDCl_3): δ 174.5 (C), 136.0 (2 C), 134.3 (C), 128.1 (CH), 128.1 (2 CH), 60.8 (CH_2), 60.0 (CH), 49.9 (CH_2),
4 35.2 (CH_2), 23.2 (CH_2), 14.0 (CH_3), 11.6 (CH_3). HRMS (ESI/Q-TOF) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{14}\text{H}_{20}\text{Cl}_2\text{NO}_2$
5 304.0865; Found 304.0865.

6 **Cp19** (ethyl 3-phenyl-2-(piperidin-1-yl)propanoate): The general procedure performed with benzyl
7 chloride (1.9 mL, 15 mmol, 3.0 equiv), ethyl glyoxylate (1.3 mL, 50% in toluene, 5.5 mmol, 1.1 equiv)
8 and piperidine (0.5 mL, 5 mmol, 1.0 equiv) afforded the title compound (0.78 g, 59%) as a yellow oil.
9 ^1H NMR (400 MHz, CDCl_3): δ 7.27–7.21 (m, 5H), 4.08–4.06 (m, 2H), 3.42 (dd, J = 9.9, 5.4 Hz, 1H),
10 3.12–3.06 (m, 1H), 2.97 (dd, J = 13.1, 4.9 Hz, 1H), 2.75–2.55 (m, 4H), 1.70–1.35 (m, 6H), 1.13 (t, J =
11 7.1 Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 171.4 (C), 138.4 (C), 129.3 (2 CH), 128.2 (2 CH), 126.3
12 (CH), 70.4 (CH), 59.9 (CH_2), 51.1 (CH_2), 35.9 (CH_2), 26.4 (3 CH_2), 24.6 (CH_2), 14.4 (CH_3). HRMS (ESI/Q-
13 TOF) m/z : $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{16}\text{H}_{24}\text{NO}_2$ 262.1801; Found 262.1800.

14 **Cp20** (methyl propylphenylalaninate) was prepared as follows. A solution of **Cp2** (235 mg, 1.0 mmol)
15 and $\text{Sc}(\text{OTf})_3$ (98 mg, 0.2 mmol, 0.2 equiv) in CH_3OH (10 mL) was heated under reflux for 18 h. Then,
16 the reaction mixture was evaporated. Purification of the residue by flash chromatography gave the
17 title compound as a yellow oil (176 mg, 79%). ^1H NMR (400 MHz, CDCl_3): δ 7.30–7.18 (m, 5H), 3.64
18 (s, 3H), 3.54 (t, J = 6.9 Hz, 1H), 2.97 (t, J = 7.0 Hz, 2H), 2.59–2.42 (m, 2H), 1.49–1.46 (m, 3H), 0.88 (t, J =
19 7.3 Hz, 3H). $^{13}\text{C}\{^1\text{H}\}$ NMR (100 MHz, CDCl_3): δ 175.1 (C), 137.2 (C), 129.0 (2 CH), 128.3 (2 CH), 126.6
20 (CH), 63.0 (CH), 51.5 (CH_3), 50.0 (CH_2), 39.6 (CH_2), 23.1 (CH_2), 11.5 (CH_3). HRMS (ESI/Q-TOF) m/z :
21 $[\text{M}+\text{H}]^+$ Calcd for $\text{C}_{13}\text{H}_{20}\text{NO}_2$ 222.1488; Found 222.1487.

22 2.2 Sample preparation for in vitro assays

23 Stock solutions to be used for the enzymatic and cellular tests were prepared by suspending the
24 compounds in DMSO at a concentration of 100 mM. Working solutions of the compounds were
25 diluted in DMSO and stored at -20°C . Potential inhibitors were added at a 1:1000 dilution to the
26 enzyme solution or culture medium.

27 2.3 Cells

28 Peripheral blood mononuclear cells (PBMCs), obtained from healthy donors by cytopheresis, were
29 provided by the Etablissement Français du Sang (EFS) and separated using Unisep tubes filled with
30 lymphocyte-separation medium (EuroBio, France). The Jurkat T cell line and human PBMCs were

1 cultivated in RPMI 1640 medium containing 10% fetal calf serum, 50 U/mL penicillin, and 50 µg/mL
2 streptomycin. For measures of cell growth, Jurkat cells were seeded at 0.1×10^6 /mL in a 24-well
3 plate and counted on days 1, 2, 3, and 6 in disposable Fast-read 10 chambers after dilution in Trypan
4 blue. THP1 and THP1 cells stably expressing IL4I1 (THP1-IL4I1) have been described previously [13]
5 and were used in proliferation experiments after irradiation at 200 Gy.

6 2.4 Determination of K_i .

7 Recombinant human IL4I1 (from R&D Systems, Inc) was diluted in PBS at 100 ng/mL and pre-
8 incubated for 30 min with various amounts of each inhibitor dissolved in DMSO (50, 25, and 2.5
9 µM) or DMSO as a control. The activity was tested in the presence of various amounts of substrate
10 (0.25, 0.5, 1, 2, or 10 mM phenylalanine) using the fluorometric IL4I1 assay described by
11 Carbonnelle-Puscian et al. [2]. The K_i for competitive inhibition was calculated using Graph Pad
12 Prism software.

13 2.5 Metabolism-based cell proliferation assay.

14 Jurkat cells were seeded at 0.1×10^6 /mL in a 96-well flat-bottom plate and incubated at 37°C in 5%
15 CO₂. At successive time points, cells were centrifuged, the medium removed, and CellTiter 96® Non-
16 Radioactive Cell Proliferation Assay reagent (Promega) added. The cells were then incubated an
17 additional 4 h before measuring the optical density at 570 nm in a plate reader (BMG Labtech
18 Fluostar Optima).

19 2.6 Apoptosis assay.

20 Cells were seeded at 5×10^5 /mL in 24-well plates, with or without the compounds at 100 µM or 10
21 µM etoposide (VP16) as a positive control, and incubated at 37°C for 24 h. Cells were then fixed and
22 permeabilized using cytox/cytoperm solution (BD Bioscience), followed by the addition of anti-
23 activated caspase 3-AlexaFluor 647 (Rabbit anti-active Caspase 3 clone C92-605, BD Pharmingen).
24 Data acquisition was performed on a Cyan ADP LX7 (Beckman Coulter) or Fortessa X20 (BD
25 Bioscience), followed by analysis using Flowjo 10 software.

26 2.7 Flow cytometry analysis of cell proliferation.

27 Jurkat cells and PBMCs were labeled with 2 µM Cell Proliferation Dye (CPD) eFluor670 (Thermo
28 Fisher) for 10 min at 37°C. Each compound or control DMSO was added to the cells before seeding
29 them at 2×10^5 /well in 96-well U-shaped plates. PBMCs were stimulated in plates pre-coated
30 overnight with an anti-CD3 antibody (clone OKT3, eBioscience) at 0.5 µg/mL in PBS. Cells were
31 collected on day 0, 3, and 6 for fluorescence acquisition using a Cyan ADP LX7 (Beckman Coulter).






1 The reversion of the effect of IL4I1 on T cell proliferation was tested by incubating PBMCs labeled
 2 with CPD (2×10^5 /well) with irradiated THP1 or THP1-IL4I1 cells (2.5×10^5 /well) in the presence of
 3 various concentrations of Cp2-SO4 dissolved in DMSO (100, 200, or 400 μ M) or the equivalent
 4 volume of DMSO. Proliferation was induced by the addition of soluble OKT3 (20 ng/mL). Cells were
 5 collected on day 5 for flow cytometry acquisition on a Fortessa X20 (BD Bioscience). FlowJo 10
 6 software was used for all data analyses and the calculation of proliferation and expansion indices.
 7 Statistical analysis (paired Student t-test) was performed using Prism 6.0.













8
 9











10 3 RESULTS

11 3.1 Synthesis of the phenylalanine derivatives

12 IL4I1 is an immunosuppressive enzyme and the ability to control its enzymatic activity could
 13 be beneficial in situations in which its ectopic or deregulated activity limits the immune response, as
 14 in cancer. We generated potential inhibitors of IL4I1 by modifying the backbone of its preferential
 15 substrate, phenylalanine, using an expedient three-component Mannich-type reaction using
 16 aldehyde derivatives of organic halides to produce α -branched amines. We also tested 7
 17 commercially available phenylalanine derivatives. The various compounds tested and their
 18 structures are shown in **Table I**.

Compound structure	Compound number	Inhibitory activity and KI (μ M)
	1	N.I.
	2-SO4	21.2 ± 5.9
	2-HCl	N.I.
	2-TFA	N.I.
	2-pMe	N.I.

	2-mMe	N.I.
	2-sulfamide	N.I.
	2-sulfamic acid	N.I.
	3	9.8 ± 4.6
	4	N.I.
	5	N.I.
	6	102.0 ± 29.7
	7	26.8 ± 6.9
	7bis	24.8 ± 12.2
	8	N.I.
	9	N.I.
	10	2800 ± 310

	11	N.I.
	12	N.I.
	13	3100 ± 560
	14	2100 ± 696
	15	N.I.
	16	N.I.
	17	N.I.
	18	49.9 ± 20.9
	19	333.9 ± 198.0
	20	1320

1
2
3
4
5
6
7

Table 1 – Structure of the phenylalanine derivatives tested as inhibitors of IL4I1. Compounds are listed with numbers. K_i of inhibition were obtained using Graph Pad Prism software and using 3 different concentrations of each compound (50, 25 and 2.5 μM) in the modified enzymatic test described by Carbonelle-Puscian [14]. Tests were performed 3 times for Cp1 to Cp17, two times for Cp18 and Cp19 and once for Cp20. N. I. means no inhibition. Values are reported in $\mu\text{M} \pm \text{S.D.}$

3.2 Characterization of the IL4I1 inhibitory capacity of the phenylalanine derivatives

We first determined the inhibitory properties of the 21 phenylalanine derivatives synthesized using our method and 7 commercially available compounds on the enzymatic activity of IL4I1. Purified recombinant human IL4I1 enzyme was pre-incubated for 30 min with decreasing amounts of each inhibitor and the IL4I1 enzymatic activity tested in the presence of variable amounts of substrate to perform a Michaelis-Menten reaction, using a variation of the fluorometric method described by Carbonnelle-Puscian [2]. Most compounds, such as Cp4, Cp5, Cp8, Cp9, Cp11, Cp15, Cp16, Cp17 and all Cp2 derivatives except Cp2-SO4, did not interfere with IL4I1 activity. Cp1, which is modified on the amino group by an aromatic CH₂CH₂N(CH₃)CH₂CH₂ group, and the di-phenyl-hydroxy-phenylalanine did not block the activity and behaved as a slightly more efficient substrate of IL4I1 than phenylalanine (data not shown). Benzoic acid has been previously suggested as an inhibitor of IL4I1 [15]. We indeed measured diminished IL4I1 activities in the presence of benzoic acid but this was due to its effect on the peroxidase used in the indirect enzymatic test to measure H₂O₂ production. Seven compounds (Cp2-SO4, Cp3, Cp6, Cp7, Cp7Bis, Cp18 and Cp19) showed inhibitory activity in the micromolar range, while Cp10, Cp13, Cp14 and Cp20 inhibited IL4I1 activity in the millimolar range, although Cp14 later became a substrate for IL4I1. The competitive inhibition of human IL4I1 activity and their K_is are reported in **Figure 1** for Cp2-SO4, Cp3, Cp6, Cp7 and Cp7Bis and in **Table 1** for all compound tested, respectively. Amongst the most effective compounds, Cp6, Cp18 and Cp19 displayed the weakest inhibitory activity. Cp2-SO4, Cp7, and Cp7Bis showed a similar inhibitory capacity, with K_i of 21.26 ± 5.9, 26.89 ± 6.91, and 24.82 ± 12.1 μM, respectively. Cp3, characterized by two Cl groups on the aromatic ring of phenylalanine and a CH₂CH₂CH₂CH₂CH₂ group on the lateral chain, showed the strongest inhibitory capacity with a K_i of 9.8 ± 4.6 μM. Some of the Cps, although active against the human enzyme, did not inhibit mouse IL4I1 (data not shown).

3.3 Cp2-SO4 and Cp6 are not toxic

We next sought to verify whether the active inhibitors interfere with cell viability and proliferation (**Figures 2, 3, & 4**). Since IL4I1 acts on T lymphocytes, we first chose the human T-cell line Jurkat for our tests. Cells were cultivated in the presence of 100 μM of each inhibitor and compared to cells to which an equivalent volume of DMSO, the vehicle of the inhibitors (1:1000 maximum), had been added. We initially counted the viable cells at various time points to generate growth curves (**Figure 2A**). Compounds such as Cp10 were extremely toxic even at doses largely inferior to the K_i values (data not shown) excluding them from any possible consideration and further work in cellular systems. Cp3 and Cp7 significantly slowed the growth of Jurkat cells, as early

1 as one day after the beginning of the culture, with no more viable cells detectable by day 6. On the
2 contrary, Cp2-SO4, Cp6, and Cp7Bis did not substantially decrease the growth of Jurkat cells, even
3 after six days. We confirmed these results using a metabolism-based cell proliferation assay: while
4 Cp3 and Cp7 strongly limited Jurkat cell proliferation, Cp2-SO4 and Cp6 had no effect (Figure 2B).
5 Finally, we analyzed the effect of Cp2-SO4 and Cp6 on the proliferation of both Jurkat cells (Figure
6 3A) and primary human T cells stimulated with an anti-CD3 antibody (Figure 3B). The cells were
7 labeled with a fluorescent cell-proliferation dye (CPD) on day 0 and the dilution of the dye induced
8 by cell division was measured by flow cytometry during the next several days. As expected, the two
9 compounds had no effect on the proliferation of Jurkat cells relative to cells treated with DMSO.
10 Interestingly, the proliferation of primary T-cells was also not affected, as established by calculation
11 of the expansion and proliferation indices (Figure 3C).

12 Thus, the candidate inhibitors Cp2-SO4 and Cp6 did not inhibit cell proliferation. However,
13 they may still induce apoptotic cell death. We evaluated this possibility by first incubating Jurkat
14 cells overnight with various compounds, including Cp2-SO4, Cp6, Cp7Bis or etoposide (VP16, a
15 clinical chemotherapy drug known for its proapoptotic properties [16]), as a positive control. We
16 then measured the appearance of the cleaved form of caspase 3, which results from its activation
17 during the early stages of apoptosis (Figure 4). Cp3 and Cp7 both induced the activation of caspase 3
18 in Jurkat cells, with Cp3 displaying a proapoptotic effect equivalent to that of VP16. In contrast,
19 neither Cp2-SO4 nor Cp6 and Cp7Bis induced significant caspase 3 activation, *i.e.* above the levels
20 detected in DMSO-treated control Jurkat cells. Cp2-SO4 and Cp6 also did not induce the apoptosis of
21 primary lymphocytes. Thus, our data suggest that the phenylalanine derivatives Cp2-SO4 and Cp6
22 are non-toxic *in vitro* for human primary cells.

23 3.4 Reversion of the inhibitory effect of IL4I1 by Cp2-SO4.

24 IL4I1 is an immunosuppressive enzyme, which mainly functions as an inhibitor of T-cell proliferation.
25 We thus decided to test whether Cp2-SO4 can reverse the antiproliferative effect of IL4I1 on T cells.
26 We stimulated PBMCs with an anti-CD3 antibody, with or without IL4I1, using the THP1 and THP1-
27 IL4I1 cell lines as described by Marquet et al. [13]. As expected, polyclonal T-cell stimulation was
28 inhibited in the presence of IL4I1 (Figure 5A). Both the mean division number, evaluated by the
29 proliferation index (Figure 5B), and the total population amplification, evaluated by the expansion
30 index (Figure 5C), were affected. This inhibition was reversed in a dose dependent manner by the
31 addition of Cp2-SO4. A proliferation level similar to that of PBMCs stimulated without IL4I1 was
32 obtained with doses of the inhibitor of 200 and 400 μ M. Thus, our data identify the first non-toxic

1 IL4I1 inhibitor that is effective in the micromolar range to reverse IL4I1 inhibitory effect and that
2 could be used to block IL4I1-induced immunosuppression.

4 4 DISCUSSION

5 IL4I1 has been implicated in tumor escape from the immune response and represents a
6 promising candidate for cancer immunotherapy. No specific inhibitors have been described for this
7 enzyme to date. Here, we characterize *in vitro*, for the first time, small phenylalanine derivatives
8 with IL4I1 inhibitory activity without an apparent toxic effect on human cells. One of the compounds
9 can reverse the blocking effect of IL4I1 on T cell proliferation, thus displaying the expected biological
10 effect.

11 Among the 28 molecules tested, only 7 showed inhibitory activity in the micromolar range.
12 Their comparison allowed us to identify several chemical features that are important for the
13 inhibitory effect and those to avoid reducing cell toxicity. Indeed, all compounds, except Cp3 and
14 Cp18, which are modified on the aromatic group of phenylalanine (*i.e.* Cp8, Cp9, Cp2-pMe, and Cp2-
15 mMe) did not show inhibitory activity, suggesting that the aromatic group may be important to
16 enter the catalytic groove of IL4I1. IL4I1 is an L-amino acid oxidase similar to those found in snake
17 venom [17]. Many of these enzymes have a strong preference for hydrophobic amino acids which
18 perfectly suit the hydrophobic binding pocket in their catalytic cavity, as shown by crystallization
19 studies. Substitutions at the phenylalanine ring may create steric hindrance at the active site [18]
20 and thus interfere with the capacity of the inhibitor to compete with the natural substrate. An
21 exception appears to be the presence of Cl groups on the aromatic ring. Indeed, these groups seem
22 to confer strong inhibitory activity to Cp3, which otherwise shares the same structure with the non-
23 active Cp5.

24 Surprisingly, Cp2-SO4 showed an inhibitory activity while Cp2 associated with different
25 counter ions was not effective. One hypothesis is that the counter ion can change the solubility of
26 the compound or its stability, thus facilitating or prolonging its inhibitory activity. This would be
27 consistent with recently reported data on two different salts of an inhibitor of the human β tryptase
28 [19]. Alternatively, the counter ion may directly participate to the inhibitory effect. This second
29 hypothesis is supported by the structural studies of Pawelek of the L-Amino acid oxidase from
30 *Calloselasma rhodostoma* which is highly homologous to IL4I1 [20]. Indeed, the α carbon atom of
31 the phenylalanine substrate forms a strong salt bridge interaction with the guanidinium group of

1 Arg90 (equivalent to Arg97 in human IL4I1) of the catalytic site. Thus, the H₂SO₄ counter ion may be
2 more efficient in competing for this interaction than the others we tested.

3 We tested the toxicity of the active molecules *in vitro* on a human T-cell line and primary
4 human PBMCs. The most active compound, Cp3, showed strong toxicity. Cp7 was also toxic, as seen
5 in both cell proliferation and the induction of apoptosis. Modification of the R3 position by a C₆H₅
6 group in the Cp7Bis molecule reduced this toxicity to values comparable to the control, while almost
7 keeping the same K_i. These observations will be important for future improvements of the active
8 compounds.

9 We tested one of the nontoxic active compounds, Cp2-SO₄, for its ability to reverse the
10 immunosuppressive action of IL4I1 *in vitro*. Indeed, the compound was able to restore T-cell
11 proliferation, even with a K_i that is only in the micromolar range. This suggests that improving the
12 backbone of any of our nontoxic compounds to more strongly inhibit the enzymatic activity of IL4I1
13 could be a valid approach to develop clinically amenable anticancer drugs.

14 5 CONCLUSION

15 In this work we have identified easily synthesizable phenylalanine derivatives endowed with IL4I1
16 inhibitory activity. Even if the non-toxic Cp2-SO₄ had a K_i in the micromolar range, it was able to
17 reverse IL4I1 inhibitory effect *in vitro* on human T cells. Since IL4I1 plays a role in tumor escape from
18 the immune system, such inhibitors may be envisioned as a basis for future development of anti-
19 cancer drugs.

21 6 ACKNOWLEDGEMENTS

22 This work was conducted with the support of Bristol-Myers Squibb Foundation for Research in
23 Immuno-Oncology, with the support of the Institut National du Cancer grant PLBIO18-255, and a
24 pre-maturation grant from SATT-idf-Innov/UPEC/IMRB/IPCME. We thank Allan Thiolat for help in
25 cell irradiation. This work has been revised by a professional English editing company (Alex Edelman
26 & associates).

28 7 CONFLICT OF INTEREST

29 The authors declare no commercial or financial conflict of interest.

8 AUTHORS' CONTRIBUTIONS

Chemical synthesis: Marc Passet, Erwan Le Gall

Conception, design and supervision: Flavia Castellano and Valérie Molinier-Frenkel

Development of methodology: Flavia Castellano

Acquisition of the data: Aurelié Dupont, Diana Djordjevic, Flavia Castellano

Analysis and interpretation of data: Flavia Castellano and Valérie Molinier-Frenkel

Writing, review, and/or revision of the manuscript: Valérie Molinier-Frenkel, Erwan Le Gall, Marc Passet and Flavia Castellano

9 FIGURE LEGENDS

Figure 1. Michaelis-Menten plots of the molecules tested. Serial dilutions of the compounds (2.5, 25, and 50 μM) dissolved in DMSO were tested on the activity of a 100 ng/mL solution of recombinant human IL4I1 using various concentrations of the enzyme substrate. Controls (0 μM) contained an equal volume (1:1000) of DMSO. The data shown are mean \pm SEM of two to four independent experiments.

Figure 2. Cps 2-SO4, 6, and 7Bis do not decrease Jurkat cell growth. **A)** 10^5 Jurkat cells per mL were cultured in the presence of 100 μM of each compound or an equivalent volume of DMSO (control). An aliquot was taken at various times (1,2,3, and 6 days) and the Trypan blue-negative cell number evaluated and reported as the percentage of control cell value. The results shown are the average of three independent experiments. **B).** 10^5 Jurkat cells per mL were seeded in a 96 well plate for 24 h before the addition of the Vibrant MTT reagent and measurement of metabolic proliferation by spectrometry. Results are reported as the percentage of the control value (cells grown in the presence of DMSO) and are the mean of three independent experiments. * $p < 0.01$, ** $p < 0.001$, *** $p < 0.0001$, paired t-test.

Figure 3. Cp2-SO4 and Cp6 do not alter cell proliferation. **A)** 10^5 Jurkat cells and **B)** PBMC were labeled with Cell Proliferation Dye 670 (CPD) and grown for up to several days in complete medium containing DMSO or 100 μM Cp2-SO4 or Cp6. Cells were analyzed each day by flow cytometry. Representative histograms are shown. **C)** The proliferation index (left) and expansion index (right) were evaluated on day 3 for stimulated PBMC using the proliferation module of FlowJo.

Figure 4. Cp2-SO4, Cp6, and Cp7Bis do not induce apoptosis. Activated caspase 3 was measured by flow cytometry after exposition of cells to the compounds at 100 μM for 24h. **A & B)** Jurkat cells. **A)** Representative histograms. **B)** Mean of three independent experiments \pm SEM. **C)** PBMC. Mean of three independent experiments \pm SEM. * $p < 0.01$, ** $p < 0.001$, *** $p < 0.0001$, paired t-test.

Figure 5. Cp2-SO4 reverses IL4I1-dependet inhibition of T-cell proliferation. 2×10^5 CPD Alexa Flour670-labeled PBMCs were incubated with 0.25×10^6 irradiated THP1 or THP1-IL4I1 cells in the presence of various concentrations of Cp2-SO4 dissolved in DMSO (100, 200, or 400 μM). Control THP1 or THP1-IL4I1 were treated with equivalent volumes of DMSO. T cell proliferation was induced by the addition of anti-CD3 antibody and evaluated on day 5 by flow cytometry. **A)** Representative

1 histogram with Cp2-SO4 at 400 μ M. **B)** Proliferation index, and **C)** expansion index. **B & C,**
2 cumulative results from four independent experiments using cells of three different donors are
3 shown as mean \pm SEM. * $p < 0.01$, ** $p < 0.001$, *** $p < 0.0001$, **** $p < 0.00001$, paired t-test.

6 10 BIBLIOGRAPHY

- 7
- 8 [1] V. Molinier-Frenkel, F. Castellano, Immunosuppressive enzymes in the tumor microenvironment,
9 *FEBS Lett* 591(19) (2017) 3135-3157.
- 10 [2] A. Carbonnelle-Puscian, C. Copie-Bergman, M. Baia, N. Martin-Garcia, Y. Allory, C. Haioun, A.
11 Cremades, I. Abd-Alsamad, J.P. Farcet, P. Gaulard, F. Castellano, V. Molinier-Frenkel, The novel
12 immunosuppressive enzyme IL4I1 is expressed by neoplastic cells of several B-cell lymphomas and
13 by tumor-associated macrophages, *Leukemia* 23(5) (2009) 952-60.
- 14 [3] F. Lasoudris, C. Cousin, A. Prevost-Blondel, N. Martin-Garcia, I. Abd-Alsamad, N. Ortonne, J.P.
15 Farcet, F. Castellano, V. Molinier-Frenkel, IL4I1: an inhibitor of the CD8(+) antitumor T-cell
16 response in vivo, *Eur J Immunol* 41(6) (2011) 1629-38.
- 17 [4] L. Bod, R. Lengagne, L. Wrobel, J.P. Ramsrott, M. Kato, M.F. Avril, F. Castellano, V. Molinier-
18 Frenkel, A. Prevost-Blondel, IL4-induced gene 1 promotes tumor growth by shaping the immune
19 microenvironment in melanoma, *Oncoimmunology* 6(3) (2017) e1278331.
- 20 [5] J.P. Ramsrott, F. Bekkat, L. Bod, M. Favier, B. Terris, A. Salomon, L. Djerroudi, K.S. Zaenker,
21 Y. Richard, V. Molinier-Frenkel, F. Castellano, M.F. Avril, A. Prevost-Blondel, Emerging role of
22 IL4-induced gene 1 as a prognostic biomarker affecting the local T cell response in human cutaneous
23 melanoma, *J Invest Dermatol* (2018).
- 24 [6] P.J. Thul, L. Akesson, M. Wiking, D. Mahdessian, A. Geladaki, H. Ait Blal, T. Alm, A. Asplund,
25 L. Bjork, L.M. Breckels, A. Backstrom, F. Danielsson, L. Fagerberg, J. Fall, L. Gatto, C. Gnann, S.
26 Hober, M. Hjelmare, F. Johansson, S. Lee, C. Lindskog, J. Mulder, C.M. Mulvey, P. Nilsson, P.
27 Oksvold, J. Rockberg, R. Schutten, J.M. Schwenk, A. Sivertsson, E. Sjostedt, M. Skogs, C. Stadler,
28 D.P. Sullivan, H. Tegel, C. Winsnes, C. Zhang, M. Zwahlen, A. Mardinoglu, F. Ponten, K. von
29 Feilitzen, K.S. Lilley, M. Uhlen, E. Lundberg, A subcellular map of the human proteome, *Science*
30 356(6340) (2017).
- 31 [7] M.F. Khirade, G. Lal, S.A. Bapat, Derivation of a fifteen gene prognostic panel for six cancers,
32 *Sci Rep* 5 (2015) 13248.
- 33 [8] G. Finak, N. Bertos, F. Pepin, S. Sadekova, M. Souleimanova, H. Zhao, H. Chen, G. Omeroglu, S.
34 Meterissian, A. Omeroglu, M. Hallett, M. Park, Stromal gene expression predicts clinical outcome in
35 breast cancer, *Nat Med* 14(5) (2008) 518-27.
- 36 [9] F. Castellano, V. Molinier-Frenkel, IL4I1: An Emerging Target to Reinvigorate Antitumor
37 Immune Responses, *Immunotherapy: Open Access* (2017).
- 38 [10] V. Molinier-Frenkel, A. Prevost-Blondel, F. Castellano, The IL4I1 Enzyme: A New Player in the
39 Immunosuppressive Tumor Microenvironment, *Cells* 8(7) (2019).
- 40 [11] E. Le Gall, C. Haurena, S. Sengmany, T. Martens, M. Troupel, Three-component synthesis of
41 alpha-branched amines under Barbier-like conditions, *J Org Chem* 74(20) (2009) 7970-3.
- 42 [12] C. Haurena, E. Le Gall, S. Sengmany, T. Martens, M. Troupel, A straightforward three-
43 component synthesis of alpha-amino esters containing a phenylalanine or a phenylglycine scaffold, *J*
44 *Org Chem* 75(8) (2010) 2645-50.
- 45 [13] J. Marquet, F. Lasoudris, C. Cousin, M. Puiffe, N. Martin-Garcia, V. Baud, F. Chéreau, J. Farcet,
46 V. Molinier-Frenkel, F. Castellano, Dichotomy between factors inducing the immunosuppressive
47 enzyme IL4I1 in B lymphocytes and mononuclear phagocytes, *European Journal of Immunology* 40
48 (2010) 2557-68.
- 49 [14] A. Carbonnelle-Puscian, C. Copie-Bergman, M. Baia, N. Martin-Garcia, Y. Allory, C. Haioun,
50 A. Cremades, I. Abd-Alsamad, J.P. Farcet, P. Gaulard, F. Castellano, V. Molinier-Frenkel, The novel

1 immunosuppressive enzyme IL4I1 is expressed by neoplastic cells of several B-cell lymphomas and
2 by tumor-associated macrophages, *Leukemia* 23(5) (2009) 952-960.

3 [15] S.S. Chavan, W. Tian, K. Hsueh, D. Jawaheer, P.K. Gregersen, C.C. Chu, Characterization of
4 the human homolog of the IL-4 induced gene-1 (Fig1), *Biochim Biophys Acta* 1576(1-2) (2002) 70-
5 80.

6 [16] C. Wang, F. Zhang, Y. Cao, M. Zhang, A. Wang, M. Xu, M. Su, M. Zhang, Y. Zhuge, Etoposide
7 Induces Apoptosis in Activated Human Hepatic Stellate Cells via ER Stress, *Sci Rep* 6 (2016) 34330.

8 [17] F. Castellano, V. Molinier-Frenkel, An Overview of L-Amino Acid Oxidase Functions from
9 Bacteria to Mammals: Focus on the Immunoregulatory Phenylalanine Oxidase IL4I1, *Molecules*
10 22(12) (2017).

11 [18] I.M. Moustafa, S. Foster, A.Y. Lyubimov, A. Vrieling, Crystal structure of LAAO from
12 *Calloselasma rhodostoma* with an L-phenylalanine substrate: insights into structure and mechanism,
13 *Journal of Molecular Biology* 364(5) (2006) 991-1002.

14 [19] Y. He, E. Orton, D. Yang, The Selection of a Pharmaceutical Salt-The Effect of the Acidity of
15 the Counterion on Its Solubility and Potential Biopharmaceutical Performance, *J Pharm Sci* 107(1)
16 (2018) 419-425.

17 [20] P.D. Pawelek, J. Cheah, R. Coulombe, P. Macheroux, S. Ghisla, A. Vrieling, The structure of L-
18 amino acid oxidase reveals the substrate trajectory into an enantiomerically conserved active site,
19 *Embo J* 19(16) (2000) 4204-15.

20
21

22 11 GLOSSARY

- 23 IL4I1 Interleukin-induced gene 1
24 PBMC Periferal Blood Mononuclear Cells

Figure 1




Figure 2





Figure 3




Figure 4








Figure 5


A




B




C





Poor proliferation



T cell proliferation restored